MY141528A - Anilinopyrazole derivatives useful for the treatment of diabetes - Google Patents

Anilinopyrazole derivatives useful for the treatment of diabetes

Info

Publication number
MY141528A
MY141528A MYPI20034545A MYPI20034545A MY141528A MY 141528 A MY141528 A MY 141528A MY PI20034545 A MYPI20034545 A MY PI20034545A MY PI20034545 A MYPI20034545 A MY PI20034545A MY 141528 A MY141528 A MY 141528A
Authority
MY
Malaysia
Prior art keywords
diabetes
treatment
derivatives useful
anilinopyrazole
anilinopyrazole derivatives
Prior art date
Application number
MYPI20034545A
Other languages
English (en)
Inventor
Joachim Rudolph
Herbert Ogutu
Alan Olague
Ning Qi
Philip L Wickens
Louis-David Cantin
Steven Magnuson
William Bullock
Ann-Marie Bullion
Libing Chen
Chih-Yuan Chuang
Sidney Liang
Dyuti Majumdar
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MY141528A publication Critical patent/MY141528A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20034545A 2002-11-27 2003-11-27 Anilinopyrazole derivatives useful for the treatment of diabetes MY141528A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
MY141528A true MY141528A (en) 2010-05-14

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20034545A MY141528A (en) 2002-11-27 2003-11-27 Anilinopyrazole derivatives useful for the treatment of diabetes

Country Status (16)

Country Link
US (2) US7265144B2 (enExample)
EP (1) EP1567517A1 (enExample)
JP (1) JP2006510728A (enExample)
KR (1) KR20050085170A (enExample)
AR (1) AR042067A1 (enExample)
AU (2) AU2003295890A1 (enExample)
BR (1) BR0316723A (enExample)
CA (1) CA2507186A1 (enExample)
HN (1) HN2003000379A (enExample)
MX (1) MXPA05004621A (enExample)
MY (1) MY141528A (enExample)
PE (1) PE20040907A1 (enExample)
PL (1) PL377164A1 (enExample)
TW (1) TW200418803A (enExample)
UY (1) UY28098A1 (enExample)
WO (2) WO2004050650A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112923A2 (en) * 2004-05-20 2005-12-01 Bayer Pharmaceuticals Corporation 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
CA2602609A1 (en) 2005-03-16 2006-09-21 Junichi Yokotani Novel anthranilic acid derivative or salt thereof
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
JP2009506127A (ja) * 2005-08-31 2009-02-12 バイエル・ヘルスケア・エルエルシー 糖尿病の処置に有用なアニリノピラゾール誘導体
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
ATE550326T1 (de) * 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
CN101522661A (zh) 2006-10-02 2009-09-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
EP2190293A4 (en) * 2007-09-28 2011-11-09 Absolute Science Inc COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES MEDIATED BY ZINC MATRIX METALLOPROTEASE
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
EP2337778A4 (en) * 2008-09-19 2012-05-09 Absolute Science Inc METHODS OF TREATING BOTULINUM TOXIN-RELATED DISEASE IN A SUBJECT
KR101444988B1 (ko) * 2008-09-25 2014-09-26 에프. 호프만-라 로슈 아게 3-아미노-인다졸 또는 3-아미노-4,5,6,7-테트라하이드로-인다졸 유도체
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
US9394269B2 (en) 2013-12-23 2016-07-19 Amazentis Sa Process-scale synthesis of urolithins
EP3805213A3 (en) 2015-06-18 2021-06-09 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
CA3066680C (en) * 2017-05-26 2022-04-12 Dongfang Shi Urat1 inhibitor for increasing uric acid excretion
WO2020227368A1 (en) * 2019-05-08 2020-11-12 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT649407A (enExample) 1960-04-14
US3790576A (en) * 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
WO1993019054A1 (en) 1992-03-26 1993-09-30 Dowelanco N-heterocyclic nitro anilines as fungicides
ATE262902T1 (de) 1994-11-10 2004-04-15 Millennium Pharm Inc Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
EP1597234B1 (en) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
WO2004050651A1 (en) 2004-06-17
EP1567517A1 (en) 2005-08-31
UY28098A1 (es) 2004-06-30
US20040157904A1 (en) 2004-08-12
US20080064734A1 (en) 2008-03-13
MXPA05004621A (es) 2005-06-08
WO2004050650A1 (en) 2004-06-17
PL377164A1 (pl) 2006-01-23
PE20040907A1 (es) 2005-01-27
BR0316723A (pt) 2005-10-18
HK1087103A1 (zh) 2006-10-06
HN2003000379A (es) 2005-12-20
KR20050085170A (ko) 2005-08-29
JP2006510728A (ja) 2006-03-30
CA2507186A1 (en) 2004-06-17
AR042067A1 (es) 2005-06-08
AU2003295890A1 (en) 2004-06-23
TW200418803A (en) 2004-10-01
US7265144B2 (en) 2007-09-04
AU2003297565A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
TW200407305A (en) Novel compounds
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
GB0222495D0 (en) Compounds
GEP20074197B (en) 5ht2c receptor modulators
WO2005046603A3 (en) Pyridine compounds
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
AU2004263179A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
TW200510303A (en) Novel compounds
TW200510416A (en) P38 inhibitors and methods of use thereof
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
TW200612892A (en) Novel compounds
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
SE0202241D0 (sv) Novel Compounds
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
AU2003260436A1 (en) Pyrimidine compounds